Pharma Foucs europe
cytiva-logo
cytiva-intensifying-concentration-and-buffer-exchange-with-counter-current-dialysis-webinar-img cytiva-intensifying-concentration-and-buffer-exchange-with-counter-current-dialysis-webinar-sm-img

Beyond TFF: Intensifying concentration and buffer exchange with counter-current dialysis

Countercurrent dialysis is an alternative to tangential flow filtration (TFF) and single-pass TFF (SPTFF) for product concentration and buffer exchange. It uses ultrafiltration membranes familiar to our industry but separates small solutes via diffusion rather than convection. Recent literature has shown its ability to exchange solutes to ≥ 99.9% and concentrate mAbs to > 250 g/L and > 50 cP [1,2]. The single-pass nature of dialysis makes it suitable for batch, connected, or continuous processing. Compared to TFF, it is simpler to operate, uses less buffer to achieve the same levels of solute exchange, and enables intensified processing.

3rd December, 2026     5:00 PM CET   |   11:00 AM EST

What you will learn:

  • How these membranes are designed and the fundamentals of their mass transport mechanism
  • The critical process parameters and one approach to process development
  • Case study data of dialysis compared with TFF and SPTFF in terms of yield, product quality, cost of goods, and manufacturing footprint
  • The technology maturity level and what will be needed to advance it from a wholistic perspective including consumable and system

Who should attend:

  • Biopharmaceuticals manufacturers
  • CDMOs
  • Persona focus: MSAT, Downstream MSAT, Process Development, Downstream Process Development

Speaker:

nick-marchand-speaker

Nick Marchand
Senior Manager, R&D, Cytiva

Nick Marchand is a manager within Cytiva's R&D department focused on bioprocess testing of new filtration technology. He holds a B.S. and Ph.D. from Rensselaer Polytechnic Institute.